Evolution of commercially available compounds for HTS.
暂无分享,去创建一个
Alexandre Varnek | Dragos Horvath | Olena Savych | Yurii S Moroz | Yurii S. Moroz | Alexander Chuprina | Yuliana Zabolotna | Dmitriy M Volochnyuk | Sergey V Ryabukhin | Duncan B Judd | D. Horvath | A. Varnek | D. Volochnyuk | S. Ryabukhin | D. Judd | A. Chuprina | Y. Zabolotna | Olena V. Savych | Yuliana Zabolotna
[1] M. R. Senger,et al. Filtering promiscuous compounds in early drug discovery: is it a good idea? , 2016, Drug discovery today.
[2] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[3] Tudor I. Oprea,et al. Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.
[4] Raymond J Winquist,et al. The fall and rise of pharmacology--(re-)defining the discipline? , 2014, Biochemical pharmacology.
[5] S. Rees,et al. Principles of early drug discovery , 2011, British journal of pharmacology.
[6] Florian Nigsch,et al. Recent trends and observations in the design of high-quality screening collections. , 2011, Future medicinal chemistry.
[7] Sarah R. Langdon,et al. Scaffold Diversity of Exemplified Medicinal Chemistry Space , 2011, J. Chem. Inf. Model..
[8] Hélène Decornez,et al. Computational Techniques to Support Hit Triage , 2015 .
[9] Tudor I. Oprea,et al. The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.
[10] D. Bojanic,et al. Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.
[11] John M. Barnard,et al. Identification of diverse database subsets using property-based and fragment-based molecular descriptions , 2002 .
[12] Miklos Feher,et al. Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..
[13] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[14] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[15] Hui Liu,et al. Comparative analyses of structural features and scaffold diversity for purchasable compound libraries , 2017, Journal of Cheminformatics.
[16] Andrew L Hopkins,et al. The Joint European Compound Library: boosting precompetitive research. , 2015, Drug discovery today.
[17] Alexander Chuprina,et al. Drug- and Lead-likeness, Target Class, and Molecular Diversity Analysis of 7.9 Million Commercially Available Organic Compounds Provided by 29 Suppliers , 2010, J. Chem. Inf. Model..
[18] David H. Drewry,et al. New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource , 2015, Scientific Reports.
[19] L. L. Elkin,et al. Just-in-Time Compound Pooling Increases Primary Screening Capacity without Compromising Screening Quality , 2015, Journal of biomolecular screening.
[20] David J. Nicholls,et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca , 2018, Nature Reviews Drug Discovery.
[21] Kelly Chibale,et al. Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis. , 2014, Chemical reviews.
[22] C. Harris,et al. How large does a compound screening collection need to be? , 2008, Combinatorial chemistry & high throughput screening.
[23] Oliver Gassmann,et al. Changing R&D models in research-based pharmaceutical companies , 2016, Journal of Translational Medicine.
[24] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[25] Andrew Bell,et al. Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy , 2012, J. Chem. Inf. Model..
[26] Roberto Todeschini,et al. Molecular descriptors for chemoinformatics , 2009 .
[27] Adam Nelson,et al. Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective. , 2015, Drug discovery today.
[28] Ian A. Watson,et al. Rules for identifying potentially reactive or promiscuous compounds. , 2012, Journal of medicinal chemistry.
[29] Christopher P Austin,et al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.
[30] Lorenz M Mayr,et al. The Future of High-Throughput Screening , 2008, Journal of biomolecular screening.
[31] Christopher B. Cooper,et al. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents. , 2013, Journal of medicinal chemistry.
[32] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[33] Anthony D. Keefe,et al. DNA-encoded chemistry: enabling the deeper sampling of chemical space , 2016, Nature Reviews Drug Discovery.
[34] Nicolas Foloppe,et al. Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totalling 2.7 Million Compounds , 2004, J. Chem. Inf. Model..
[35] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[36] Robin B. Gasser,et al. Screening of the ‘Open Scaffolds’ collection from Compounds Australia identifies a new chemical entity with anthelmintic activities against different developmental stages of the barber's pole worm and other parasitic nematodes , 2017, International journal for parasitology. Drugs and drug resistance.
[37] Matthew D. Troutman,et al. Experimental Screening Strategies to Reduce Attrition Risk , 2015 .
[38] Dragos Horvath,et al. Chemical Data Visualization and Analysis with Incremental Generative Topographic Mapping: Big Data Challenge , 2015, J. Chem. Inf. Model..
[39] W Frank An,et al. Cell-Based Assays for High-Throughput Screening , 2010, Molecular biotechnology.
[40] M. Prunotto,et al. Opportunities and challenges in phenotypic drug discovery: an industry perspective , 2017, Nature Reviews Drug Discovery.
[41] Jonathan B. Baell,et al. Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350, 000 Compounds , 2013, J. Chem. Inf. Model..
[42] Stephen D. Pickett,et al. Research Papers) Design of a Compound Screening Collection for use in High Throughput Screening , 2004 .
[43] Ramaswamy Nilakantan,et al. A novel approach to combinatorial library design. , 2002, Combinatorial chemistry & high throughput screening.
[44] D. Horvath,et al. ISIDA Property‐Labelled Fragment Descriptors , 2010, Molecular informatics.
[45] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[46] W. Patrick Walters,et al. A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.
[47] Raman Parkesh,et al. Structural enrichment of HTS compounds from available commercial libraries , 2012 .
[48] Vinay Prasad,et al. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval , 2017, JAMA internal medicine.
[49] G. V. Paolini,et al. Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.
[50] Asher Mullard,et al. European Lead Factory opens for business , 2013, Nature Reviews Drug Discovery.
[51] W. Janzen,et al. Screening technologies for small molecule discovery: the state of the art. , 2014, Chemistry & biology.
[52] Nathan Brown,et al. Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules , 2012, J. Chem. Inf. Model..
[53] H. Verheij,et al. Leadlikeness and structural diversity of synthetic screening libraries , 2006, Molecular Diversity.
[54] Ola Engkvist,et al. On the Relationship between Molecular Hit Rates in High-Throughput Screening and Molecular Descriptors , 2014, Journal of biomolecular screening.
[55] Kuo-Chen Chou,et al. Assessment of chemical libraries for their druggability , 2005, Comput. Biol. Chem..
[56] Clive Green,et al. Consolidating a Distributed Compound Management Capability into a Single Installation , 2016, Journal of laboratory automation.
[57] Mark J Wigglesworth,et al. Increasing the delivery of next generation therapeutics from high throughput screening libraries. , 2015, Current opinion in chemical biology.
[58] Stefan Günther,et al. The Purchasable Chemical Space: A Detailed Picture , 2015, J. Chem. Inf. Model..
[59] Dragos Horvath,et al. Generative Topographic Mapping Approach to Chemical Space Analysis , 2017 .
[60] Stephen D Pickett,et al. Nuisance Compounds, PAINS Filters, and Dark Chemical Matter in the GSK HTS Collection , 2018, SLAS discovery : advancing life sciences R & D.
[61] Thierry Kogej,et al. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. , 2013, Drug discovery today.
[62] Valerie J Gillet,et al. New directions in library design and analysis. , 2008, Current opinion in chemical biology.
[63] A. Gorse. Diversity in medicinal chemistry space. , 2006, Current topics in medicinal chemistry.
[64] Jens Loesel,et al. Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files , 2016, Molecular Diversity.
[65] Harren Jhoti,et al. Twenty years on: the impact of fragments on drug discovery , 2016, Nature Reviews Drug Discovery.
[66] Channa K. Hattotuwagama,et al. Lead-oriented synthesis: a new opportunity for synthetic chemistry. , 2012, Angewandte Chemie.
[67] P. Petrone,et al. Aggregated Compound Biological Signatures Facilitate Phenotypic Drug Discovery and Target Elucidation. , 2016, ACS chemical biology.